Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, T-Cell, Peripheral 1 Lymphoma, Extranodal NK-T-Cell 1

Interventions

pembrolizumab 73 Carboplatin 60 Cyclophosphamide 59 Nivolumab 52 Paclitaxel 47 Gemcitabine 44 Cisplatin 43 Dexamethasone 41 Radiotherapy 36 Rituximab 32 Capecitabine 32 Bevacizumab 29 Docetaxel 28 fludarabine 27 atezolizumab 26 Cytarabine 26 avelumab 24 Trastuzumab 23 Oxaliplatin 23 Lenalidomide 23 Cetuximab 23 venetoclax 22 Ipilimumab 22 Fluorouracil 22 Azacitidine 22 Temozolomide 21 130-nm albumin-bound paclitaxel 21 fludarabine phosphate 20 Filgrastim 20 Bortezomib 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Terminated × Ice × Clear all

NCT04425070 2026-01-05

TOUCH

Antengene Corporation

Phase 1/2 Terminated

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡